SXTC
China SXT Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.22
P/S
1.74
EV/EBITDA
9.06
DCF Value
$35.34
FCF Yield
-62.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
25.5%
Operating Margin
-224.1%
Net Margin
-274.4%
ROE
-14.7%
ROA
-9.5%
ROIC
-9.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $455.7K | $-1.3M | $-0.51 |
| FY 2025 | $1.7M | $-3.3M | $-8.18 |
| Q3 2025 | $455.7K | $-1.3M | $-0.51 |
| Q2 2025 | $414.7K | $-401.3K | $-0.99 |
Company Info
Sector
Healthcare
Industry
—
Country
CN
Exchange
NASDAQ
Beta
1.75
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.